AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02177760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Study NCT01334034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0123-0000-0338
Description: Subjects will be randomised to receive a single dose of NNC 0123-0000-0338 (tablet), at 7 escalating dose levels. Progression to next dose level will be based on a safety evaluation.
Study NCT01334034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will receive a single dose of placebo (tablet), as a comparator to NNC 0123-0000-0338 at all dose levels. Placebo dose remains the same at all dose levels.
Study NCT01334034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: As an open label active comparator, a single dose of insulin glargine will be administered subcutaneously (under the skin), at all dose levels. Insulin glargine dose remains the same at all dose levels.
Study NCT02524353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiac surgery
Description: Surgical cardiac procedures despite benefiting the clinical condition of the patient with potential increased survival and reduced risk of death can cause both immediate and long-term functional changes that may influence the appropriate re-inclusion of this individual the daily life practices as well as labor and social activities. Such changes resulting from surgical procedures in the short term are already well documented but the occurrence of these same changes in the late period and its influence on patient's daily lives are not well documented.
Study NCT01931800 — intervention group
Intervention type: BIOLOGICAL
Intervention: Sampling of blood
Study NCT03389971 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: catheter-directed thrombolysis
Description: catheter-directed thrombolysis with commercially available multi-sidehole catheter or USAT catheter
Study NCT03389971 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: catheter-directed thrombolysis
Description: catheter-directed thrombolysis with commercially available multi-sidehole catheter or USAT catheter
Study NCT03346460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tongue Scraping
Description: Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating.
Study NCT03346460 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: aPDT
Description: One session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. The excess will be removed with a sucker in order to keep the surface wet with the PS itself, without using water. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
Study NCT03346460 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tongue scraper and aPDT
Description: Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating. After, one session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
Study NCT00954044 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Randomized Exercise Intervention
Description: The Exercising Together training group will participate in 6 months of supervised, progressive partnered resistance exercise.~Couples will participate in 2 exercise sessions a week for 6 months.
Study NCT00954044 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Randomized Exercise Intervention
Description: Couples will continue doing their usual daily activities for 6 months
Study NCT02518009 — intervention group
Intervention type: OTHER
Intervention: Genetic men treated with estrogen
Description: Observational during estrogen treatment
Study NCT02518009 — intervention group
Intervention type: OTHER
Intervention: Genetic women treated with androgen
Description: Observational during androgen treatment
Study NCT01196052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: Trastuzumab emtansine was provided as a single-use lyophilized formulation in a glass vial.
Study NCT01638988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 1. cycle 2000 mg of Metformin : Day 1 to day 30; beginning with 1/2 tablet by day with an increasing until 4 pills by day~2. to 6 cycle 2000 mg of Metformin : Day 1 ot day 30; 4 pills of Metformin by day Positive pregnancy test : 4 pills of Metformin by day until 12 weeks of pregnancy
Study NCT01638988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate
Description: Cycle 1: Day 3 to day 7; 50 mg; 1 tablet of Clomiphene Citrate by day Cycle 2: Day 3 to day 7; 100 mg; 1 tablet of Clomiphene Citrate two times a day Cycle 3 to 6 : Day 3 to day 7; 150 mg; 1 tablet of Clomiphene Citrate 3 times a day
Study NCT01653626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: package of 3 interventions
Description: Emergency Obstetric Care training, social marketing approach and link TBS with public sector services
Study NCT00905853 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: Intracardiac electrode catheters are placed via central vasculature to identify myocardial scar, and surviving conduction channels within the scar which form the substrate for ventricular tachycardia. Radiofrequency energy is applied to these sites, interrupting the VT circuits.
Study NCT00905853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escalated Antiarrhythmic Therapy
Description: Patients who have 'failed' antiarrhythmic therapy (except amiodarone) will be prescribed: Amiodarone 400 mg twice daily for 2 weeks, followed by 400 mg/day for 4 weeks, followed by 200 mg/day thereafter.~Patients who 'failed' amiodarone (less than 300mg/day) will be prescribed: Amiodarone 400 mg three times a day for 2 weeks, followed by 400 mg/day for 1 week and 300 mg/day thereafter.~Patients who 'failed' amiodarone (greater or equal to 300mg/day) will be prescribed: Amiodarone at the current dose with the addition of mexiletine 400 to 800 mg/day
Study NCT02344888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate and Prednisolone
Description: Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of the cycle) and prednisolone (5 mg/day for 10 consecutive days from day 2 of the cycle)
Study NCT02344888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate and folic acid
Description: Women will receive clomiphene citrate alone (150 mg/day for 5 consecutive days from day 2 of the cycle) and folic acid (0.5 mg/day for 10 consecutive days from day 2 of the cycle)
Study NCT02078687 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enfamil HM fortifier, Mead Johnson
Description: Enfamil was added to a small amount of mothers expressed milk and given in a bottle or with a small cup every day. Group 2 (HMF) received 5 packets each day for 4 month containing; 17.5 kcal, 1.375 g protein/ 5 packets
Study NCT02078687 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enfalac Premature Formula, Mead Johnson Nutritionals
Description: Group 3 received Enfalac containing:~68 kcal, 2 g protein, 7.4 g carbohydrate, 3.5 g fat/ 100 ml
Study NCT02078687 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mothers own milk
Description: Group 1 received mothers own milk without fortification
Study NCT02438709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COX-2 inhibitor
Description: oral COX-2 inhibitor intake 60mg qd
Study NCT03477864 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given via intraprostatic injection
Study NCT01963611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copaxone 20 mg
Description: Plovamer acetate was administered at a dose of 3 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
Study NCT01963611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plovamer acetate 3 mg
Description: Plovamer acetate was administered at a dose of 10 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
Study NCT01963611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plovamer acetate 10 mg
Description: Plovamer acetate was administered as two subcutaneous injection of 10 mg weekly for 40 weeks up to a maximum of 14 months.
Study NCT01963611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plovamer acetate 20 mg
Description: Copaxone was administered at a dose of 20 mg as subcutaneous injection once daily for 40 weeks up to a maximum of 14 months.
Study NCT04736875 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler ultrasound study
Description: Transcutaneous Doppler ultrasound (DUS) study was performed at the mid brachial artery to assess diameter, VF and RI, and at the mid segment of the efferent vein to assess the diameter and wall thickness.
Study NCT02058095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Tadalafil 5 mg tablet. Daily. Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is >95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil.~At 2 weeks (± 5 days) if blood pressure is> 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil.~At 4 weeks(± 5 days) if blood pressure is > 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil.
Study NCT02058095 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet. Daily. Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is >95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo.~At 2 weeks (± 5 days) if blood pressure is> 100 than add 1 tab of placebo to make a total of 3 tablets of placebo.~At 4 weeks(± 5 days) if blood pressure is > 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo.
Study NCT02429466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine (SGI-110)
Description: SGI-110 will be given subcutaneously, daily, 30 mg/m2 on days (1-5) followed by cisplatin 100mg/m2 on day 8 every 4 weeks.
Study NCT02479490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone + Everolimus
Description: Prednisone + Everolimus: Everolimus is formulated as tablets of 5-10 mg strength, blister-packed under aluminium foil in units of 10 tablets. Prednisone will be dispensed to patients at the dose of 5 mg twice daily (BID). Everolimus at dose of 10 mg (one 10 mg tablet or two 5 mg tablets). Both drugs will be self-administered orally, continuously from Day 1 (Visit 2) until progression of disease, unacceptable toxicity, death or discontinuation for any other reason.~A treatment cycle consists of 28 days.
Study NCT03477864 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Undergo SBRT
Study NCT03477864 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy
Study NCT03477864 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 Monoclonal Antibody REGN2810
Description: Given IV
Study NCT01390493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neurofeedback training
Description: training of individual alpha frequency, 10 sessions, each 15 min
Study NCT03340610 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Alflibercept
Description: Intravitreal Injection
Study NCT03109171 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Laryngopharyngeal sensory test
Description: The sensory measurements will include thresholds for psychophysical sensory thresholds at the velopharynx, hypopharynx and aryepiglottic folds
Study NCT03584867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: refresher training at six months
Description: a 5 cycles of 30:2 compression to ventilation ratio will be offered to experimental group at six months from BLS certification.
Study NCT04003233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SDS
Description: The SDS will be added to a traditional growing rod (TGR) of 4.5 or 5.5mm.
Study NCT04003233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MID-C
Description: The MID-C system consists of a unilateral one-way ratchet rod that is connected to the spine with polyaxial connectors
Study NCT00963274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Starting dose: 1.3 mg/sq m
Study NCT00963274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Starting dose: 8 mg/sq m
Study NCT05779982 — intervention group
Intervention type: PROCEDURE
Intervention: Sentinel lymph node biopsy followed by axillary lymph node dissection
Description: This is a retrospective study to determine the feasibility of sentinel lymph node biopsy (SLNB) after neoadjuvant systemic therapy (NAST) according to response to NAST and breast cancer subtypes. All patients received SLNB followed by axillary lymph node dissection after NAST.
Study NCT00777010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: carbohydrate restricted diet
Study NCT00777010 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy high carbohydrate diet
Description: higher carbohydrate diet
Study NCT01324232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-923-45
Description: AVP-923-45 (dextromethorphan 45 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
Study NCT01324232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-923-30
Description: AVP-923-30 (dextromethorphan 30 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
Study NCT01324232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-923-20
Description: AVP-923-20 (dextromethorphan 20 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
Study NCT01324232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
Study NCT01168661 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: Participants in this intervention arm will practice yoga (physical postures, breathing exercises, and meditation) >= 5 times a week (twice in a supervised group and the rest on their own). Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. They will follow this schedule for 20 weeks.
Study NCT01168661 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness based cog psychotherapy
Description: Participants in this arm will attend a weekly group meeting to practice mindfulness based cognitive psychotherapy. They will also practice >= 4 time a week on their own. Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. Participants will follow this schedule for 20 weeks.
Study NCT01168661 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive psychotherapy
Description: Participants in this arm will attend a weekly group meeting to practice cognitive psychotherapy. They will also practice >= 4 time a week on their own. Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. Participants will follow this schedule for 20 weeks.
Study NCT01789814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Patients will be randomized to prasugrel or clopidogrel to assess the effect of these drugs on inhibition of platelet aggregation following the cessation of bivalirudin therapy.
Study NCT01789814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 600 mg as a loading dose immediately prior to the start of procedure and 75 mg daily thereafter
Study NCT03317756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Educational Intervention
Description: Patients will view 5-6 videos that will help them with pre-identified patient barriers to achieving RA low disease activity
Study NCT03317756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Control
Description: Patients will receive an attention control
Study NCT05325905 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gingival crevicular fluid sampling
Description: GCF sampling and clinical periodontal measurements were performed
Study NCT03714529 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L1
Description: IO103 is a anti-cancer therapy consisting of a synthetic PD-L1-derived peptide.
Study NCT01317589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: T = 0~* start methadone 2 x 2,5 mg or fentanyl patch 12 μg/uur~* breakthrough medication: 50 µg fentanyl nose spray or fentanyl stick 400 µg till 6x/day~T=1~1 week~* if necessary increase dose strong opioid with 50%~T=2 3 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T=3 5 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T = 4 9 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%
Study NCT01317589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methadone
Description: T = 0~* start methadone 2 x 2,5 mg or fentanyl patch 12 μg/uur~* breakthrough medication: 50 µg fentanyl nose spray or fentanyl stick 400 µg till 6x/day~T=1~1 week~* if necessary increase dose strong opioid with 50%~T=2 3 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T=3 5 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T = 4 9 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%
Study NCT00798226 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: n-3 fatty acid
Description: Oral intake of 4 capsules daily from week 24 of gestation to 1 week after delivery
Study NCT00798226 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: olive oil
Description: Oral intake of 4 capsules (1 g) daily from 24 weeks of gestation to 1 week after delivery
Study NCT02042937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise to improve gluteus maximus recruitment
Study NCT00944203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipomea pes-caprae ointment
Description: Ipomea pes-caprae ointment will be applied twice a day as an add-on therapy.
Study NCT02330848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Walnut Ad libitum diet
Description: Participants will be provided 392 grams of walnuts per week (56g or 2 oz/day) to include in their diet. Their calorie intake will not be subsequently monitored or regulated, and thus will be allowed to float ad libitum
Study NCT01019447 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl Plus
Description: Triclosan-coated polyglactin 910 antimicrobial sutures (Vicryl Plus)
Study NCT01019447 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl
Description: Polyglactin 910 antimicrobial sutures (Vicryl)